Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study

Author(s):
Mocroft, A.; Lundgren, J.D.; Ross, M.; Fux, C.A.; Reiss, P.; Moranne, O.; Morlat, P.; Monforte, A.D.; Kirk, O.; Ryom, L.; Data Collection Adverse Events
Published
2016
Publication type
Article / Letter to editor

Abstract

Interpretation In people with normal renal function, the annual incidence of chronic kidney disease increased for up to 6 years of exposure to tenofovir disoproxil fumarate, ritonavir- boosted atazanavir, or ritonavir- boosted lopinavir therapy. Although the absolute number of new cases of chronic kidney disease was modest, treatment with these antiretrovirals might result in an increasing and cumulative risk of chronic kidney disease. Patients on potentially nephrotoxic antiretrovirals or at high risk of chronic kidney disease should be closely monitored.

Date issued
2016-01-01
Language
English
Publisher
ELSEVIER INC
Is part of
The Lancet HIV (2016), Vol. 3, no. 1, p. E23-E32
hdl
1887/99395
doi
10.1016/S2352-3018(15)00211-8